Fundraising FoxPannextherapeutics
2 known investors
Find your way into Pannextherapeutics
Sign up to see every warm intro you have to Pannextherapeutics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Pannextherapeutics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Pannex Therapeutics develops a novel drug class of proprietary Pannexin 1 (Panx1) channel blockers, targeting disease-relevant pathways shared across neurological disorders and cancer. Its initial programs focus on chronic neuropathic pain and triple-negative breast cancer, with plans to expand into broader neurology and oncology indications.
Founders & leadership
Investors · 2
Frequently asked questions
- What does Pannextherapeutics do?
- Pannex Therapeutics develops a novel drug class of proprietary Pannexin 1 (Panx1) channel blockers, targeting disease-relevant pathways shared across neurological disorders and cancer. Its initial programs focus on chronic neuropathic pain and triple-negative breast cancer, with plans to expand into broader neurology and oncology indications.
- Who founded Pannextherapeutics?
- Pannextherapeutics was founded by David Bravo, Thomas Gerlach, Gerhard Gross, Dr. David Bravo.
- Who are Pannextherapeutics's investors?
- Pannextherapeutics's investors include SOSV, Ganesha Lab.